vs
Side-by-side financial comparison of AMICUS THERAPEUTICS, INC. (FOLD) and SunOpta Inc. (STKL). Click either name above to swap in a different company.
SunOpta Inc. is the larger business by last-quarter revenue ($205.4M vs $185.2M, roughly 1.1× AMICUS THERAPEUTICS, INC.). AMICUS THERAPEUTICS, INC. runs the higher net margin — 0.9% vs 0.4%, a 0.5% gap on every dollar of revenue. On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs 16.6%). AMICUS THERAPEUTICS, INC. produced more free cash flow last quarter ($16.0M vs $12.1M). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs 7.4%).
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
SunOpta, Inc. is a multi-national food and mineral company headquartered in Eden Prairie, Minnesota and founded in 1973 in Canada.
FOLD vs STKL — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $185.2M | $205.4M |
| Net Profit | $1.7M | $816.0K |
| Gross Margin | 85.7% | 12.4% |
| Operating Margin | 8.6% | 3.3% |
| Net Margin | 0.9% | 0.4% |
| Revenue YoY | 23.7% | 16.6% |
| Net Profit YoY | -88.5% | 113.1% |
| EPS (diluted) | $0.00 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $185.2M | — | ||
| Q3 25 | $169.1M | $205.4M | ||
| Q2 25 | $154.7M | $191.5M | ||
| Q1 25 | $125.2M | $201.6M | ||
| Q4 24 | $149.7M | $193.9M | ||
| Q3 24 | $141.5M | $175.9M | ||
| Q2 24 | $126.7M | $169.5M | ||
| Q1 24 | $110.4M | $184.4M |
| Q4 25 | $1.7M | — | ||
| Q3 25 | $17.3M | $816.0K | ||
| Q2 25 | $-24.4M | $4.4M | ||
| Q1 25 | $-21.7M | $4.8M | ||
| Q4 24 | $14.7M | $-8.7M | ||
| Q3 24 | $-6.7M | $-6.2M | ||
| Q2 24 | $-15.7M | $-5.3M | ||
| Q1 24 | $-48.4M | $2.9M |
| Q4 25 | 85.7% | — | ||
| Q3 25 | 88.5% | 12.4% | ||
| Q2 25 | 90.2% | 14.8% | ||
| Q1 25 | 90.7% | 15.0% | ||
| Q4 24 | 90.1% | 10.9% | ||
| Q3 24 | 90.6% | 13.0% | ||
| Q2 24 | 91.1% | 12.5% | ||
| Q1 24 | 87.7% | 16.8% |
| Q4 25 | 8.6% | — | ||
| Q3 25 | 20.3% | 3.3% | ||
| Q2 25 | -6.1% | 5.5% | ||
| Q1 25 | -6.3% | 5.2% | ||
| Q4 24 | 10.7% | 1.4% | ||
| Q3 24 | 15.3% | 0.5% | ||
| Q2 24 | 11.8% | 1.2% | ||
| Q1 24 | -25.1% | 5.5% |
| Q4 25 | 0.9% | — | ||
| Q3 25 | 10.2% | 0.4% | ||
| Q2 25 | -15.8% | 2.3% | ||
| Q1 25 | -17.3% | 2.4% | ||
| Q4 24 | 9.8% | -4.5% | ||
| Q3 24 | -4.8% | -3.5% | ||
| Q2 24 | -12.4% | -3.1% | ||
| Q1 24 | -43.9% | 1.6% |
| Q4 25 | $0.00 | — | ||
| Q3 25 | $0.06 | $0.01 | ||
| Q2 25 | $-0.08 | $0.03 | ||
| Q1 25 | $-0.07 | $0.04 | ||
| Q4 24 | $0.05 | $-0.08 | ||
| Q3 24 | $-0.02 | $-0.05 | ||
| Q2 24 | $-0.05 | $-0.04 | ||
| Q1 24 | $-0.16 | $0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $293.5M | $2.2M |
| Total DebtLower is stronger | $392.7M | $250.8M |
| Stockholders' EquityBook value | $274.2M | $162.8M |
| Total Assets | $949.9M | $694.1M |
| Debt / EquityLower = less leverage | 1.43× | 1.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $293.5M | — | ||
| Q3 25 | $263.8M | $2.2M | ||
| Q2 25 | $231.0M | $2.2M | ||
| Q1 25 | $250.6M | $2.3M | ||
| Q4 24 | $249.9M | $1.6M | ||
| Q3 24 | $249.8M | $2.9M | ||
| Q2 24 | $260.1M | $3.2M | ||
| Q1 24 | $239.6M | $1.5M |
| Q4 25 | $392.7M | — | ||
| Q3 25 | $392.0M | $250.8M | ||
| Q2 25 | $391.3M | $263.3M | ||
| Q1 25 | $390.7M | $260.6M | ||
| Q4 24 | $390.1M | $265.2M | ||
| Q3 24 | $389.5M | $289.9M | ||
| Q2 24 | $388.9M | $303.1M | ||
| Q1 24 | $388.4M | $258.8M |
| Q4 25 | $274.2M | — | ||
| Q3 25 | $230.4M | $162.8M | ||
| Q2 25 | $204.3M | $159.8M | ||
| Q1 25 | $193.6M | $154.8M | ||
| Q4 24 | $194.0M | $148.6M | ||
| Q3 24 | $178.8M | $155.0M | ||
| Q2 24 | $132.5M | $158.8M | ||
| Q1 24 | $130.7M | $163.6M |
| Q4 25 | $949.9M | — | ||
| Q3 25 | $868.8M | $694.1M | ||
| Q2 25 | $815.3M | $704.9M | ||
| Q1 25 | $789.8M | $690.7M | ||
| Q4 24 | $785.0M | $668.5M | ||
| Q3 24 | $786.6M | $699.3M | ||
| Q2 24 | $749.5M | $704.7M | ||
| Q1 24 | $721.8M | $671.8M |
| Q4 25 | 1.43× | — | ||
| Q3 25 | 1.70× | 1.54× | ||
| Q2 25 | 1.92× | 1.65× | ||
| Q1 25 | 2.02× | 1.68× | ||
| Q4 24 | 2.01× | 1.78× | ||
| Q3 24 | 2.18× | 1.87× | ||
| Q2 24 | 2.93× | 1.91× | ||
| Q1 24 | 2.97× | 1.58× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.3M | $16.3M |
| Free Cash FlowOCF − Capex | $16.0M | $12.1M |
| FCF MarginFCF / Revenue | 8.6% | 5.9% |
| Capex IntensityCapex / Revenue | 0.2% | 2.1% |
| Cash ConversionOCF / Net Profit | 9.62× | 20.03× |
| TTM Free Cash FlowTrailing 4 quarters | $29.8M | $36.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.3M | — | ||
| Q3 25 | $35.7M | $16.3M | ||
| Q2 25 | $-26.5M | $-4.5M | ||
| Q1 25 | $7.8M | $22.3M | ||
| Q4 24 | $-3.9M | $33.1M | ||
| Q3 24 | $-23.0M | $17.2M | ||
| Q2 24 | $22.7M | $-5.6M | ||
| Q1 24 | $-29.7M | $5.3M |
| Q4 25 | $16.0M | — | ||
| Q3 25 | $35.3M | $12.1M | ||
| Q2 25 | $-28.9M | $-9.2M | ||
| Q1 25 | $7.5M | $9.5M | ||
| Q4 24 | $-4.2M | $24.0M | ||
| Q3 24 | $-23.3M | $11.7M | ||
| Q2 24 | $21.6M | $-15.3M | ||
| Q1 24 | $-31.5M | $-2.3M |
| Q4 25 | 8.6% | — | ||
| Q3 25 | 20.9% | 5.9% | ||
| Q2 25 | -18.7% | -4.8% | ||
| Q1 25 | 6.0% | 4.7% | ||
| Q4 24 | -2.8% | 12.4% | ||
| Q3 24 | -16.5% | 6.6% | ||
| Q2 24 | 17.0% | -9.0% | ||
| Q1 24 | -28.5% | -1.2% |
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.2% | 2.1% | ||
| Q2 25 | 1.6% | 2.5% | ||
| Q1 25 | 0.2% | 6.3% | ||
| Q4 24 | 0.2% | 4.7% | ||
| Q3 24 | 0.3% | 3.2% | ||
| Q2 24 | 0.9% | 5.7% | ||
| Q1 24 | 1.6% | 4.1% |
| Q4 25 | 9.62× | — | ||
| Q3 25 | 2.06× | 20.03× | ||
| Q2 25 | — | -1.03× | ||
| Q1 25 | — | 4.63× | ||
| Q4 24 | -0.27× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
STKL
| Beverages And Broths | $161.4M | 79% |
| Fruit Snacks | $40.9M | 20% |
| Ingredients | $3.1M | 2% |
